• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一种联合的长链非编码RNA特征作为卵巢癌的候选预后生物标志物

A Combined Long Noncoding RNA Signature as a Candidate Prognostic Biomarker for Ovarian Cancer.

作者信息

Li Hui, Wang Shuoer, Yao Qianlan, Liu Yan, Yang Jing, Xu Lun, Yang Gong

机构信息

Central Laboratory, the Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.

Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

出版信息

Front Oncol. 2021 May 27;11:624240. doi: 10.3389/fonc.2021.624240. eCollection 2021.

DOI:10.3389/fonc.2021.624240
PMID:34123783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8191461/
Abstract

AIMS

Dysregulated long noncoding RNAs (lncRNAs) contributing to ovarian cancer (OC) development may serve as prognostic biomarker. We aimed to explore a lncRNA signature to serve as prognostic biomarker of OC.

METHODS

Univariate Cox regression was conducted on the lncRNA expression dataset from the TCGA cohort, and 246 genes significantly associated with survival were retained for building a model. A random forest survival model was carried out, and a model was developed using 6 genes with the highest frequency. The selected genes were applied in a Cox multivariate regression model for prognostic prediction by calculating the risk score. We also used CCK-8, EdU, and colony formation assays to validate the function of these lncRNAs in OC cells.

RESULTS

This study confirmed that the 6-lncRNA combined signature was related to OC prognosis. Systematic analysis demonstrated that lncRNA-associated genes were enriched in oncogenic signalling pathways. Five out of the 6 lncRNAs participated in OC proliferation.

CONCLUSION

We established a 6-lncRNA combined signature for OC prognosis, which may serve as powerful prognostic biomarker for OC after further validation.

摘要

目的

参与卵巢癌（OC）发生发展的长链非编码RNA（lncRNA）失调可能作为预后生物标志物。我们旨在探索一种lncRNA特征作为OC的预后生物标志物。

方法

对来自TCGA队列的lncRNA表达数据集进行单变量Cox回归分析，保留246个与生存显著相关的基因用于构建模型。进行随机森林生存模型分析，并使用出现频率最高的6个基因构建模型。通过计算风险评分，将所选基因应用于Cox多变量回归模型进行预后预测。我们还使用CCK-8、EdU和集落形成实验来验证这些lncRNA在OC细胞中的功能。

结果

本研究证实6-lncRNA联合特征与OC预后相关。系统分析表明，lncRNA相关基因在致癌信号通路中富集。6个lncRNA中有5个参与OC增殖。

结论

我们建立了用于OC预后的6-lncRNA联合特征，经进一步验证后可能作为OC有力的预后生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec97/8191461/dfba8f8e588e/fonc-11-624240-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec97/8191461/9d50fd103c21/fonc-11-624240-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec97/8191461/68adfdb0cd49/fonc-11-624240-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec97/8191461/5104a352766d/fonc-11-624240-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec97/8191461/da44e262df2a/fonc-11-624240-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec97/8191461/9494b437ae23/fonc-11-624240-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec97/8191461/dfba8f8e588e/fonc-11-624240-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec97/8191461/9d50fd103c21/fonc-11-624240-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec97/8191461/68adfdb0cd49/fonc-11-624240-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec97/8191461/5104a352766d/fonc-11-624240-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec97/8191461/da44e262df2a/fonc-11-624240-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec97/8191461/9494b437ae23/fonc-11-624240-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec97/8191461/dfba8f8e588e/fonc-11-624240-g006.jpg

相似文献

1
A Combined Long Noncoding RNA Signature as a Candidate Prognostic Biomarker for Ovarian Cancer.一种联合的长链非编码RNA特征作为卵巢癌的候选预后生物标志物
Front Oncol. 2021 May 27;11:624240. doi: 10.3389/fonc.2021.624240. eCollection 2021.
2
A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.一种基于共表达网络分析和五种长链非编码RNA表达水平的新型卵巢癌风险评分系统。
BMC Med Genet. 2019 Jun 10;20(1):103. doi: 10.1186/s12881-019-0832-9.
3
A Potential Immune-Related Long Non-coding RNA Prognostic Signature for Ovarian Cancer.一种潜在的卵巢癌免疫相关长链非编码RNA预后标志物
Front Genet. 2021 Jul 21;12:694009. doi: 10.3389/fgene.2021.694009. eCollection 2021.
4
Identification and validation of lncRNAs involved in m6A regulation for patients with ovarian cancer.卵巢癌患者中参与m6A调控的长链非编码RNA的鉴定与验证
Cancer Cell Int. 2021 Jul 8;21(1):363. doi: 10.1186/s12935-021-02076-7.
5
A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.基于免疫相关长非编码 RNA 的上皮性卵巢癌预后模型。
J Ovarian Res. 2022 Jan 15;15(1):8. doi: 10.1186/s13048-021-00930-w.
6
Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.鉴定五个长链非编码 RNA 标志物以改善肝细胞癌患者的预后预测。
World J Gastroenterol. 2018 Aug 14;24(30):3426-3439. doi: 10.3748/wjg.v24.i30.3426.
7
Four Prognosis-Associated lncRNAs Serve as Biomarkers in Ovarian Cancer.四种与预后相关的长链非编码RNA在卵巢癌中作为生物标志物
Front Genet. 2021 Jul 2;12:672674. doi: 10.3389/fgene.2021.672674. eCollection 2021.
8
Identification and Validation of a Prognostic lncRNA Signature for Hepatocellular Carcinoma.肝细胞癌预后lncRNA特征的鉴定与验证
Front Oncol. 2020 Jun 10;10:780. doi: 10.3389/fonc.2020.00780. eCollection 2020.
9
Identification of a RNA-Seq Based 8-Long Non-Coding RNA Signature Predicting Survival in Esophageal Cancer.基于RNA测序的8长非编码RNA特征预测食管癌生存情况的鉴定
Med Sci Monit. 2016 Dec 28;22:5163-5172. doi: 10.12659/msm.902615.
10
Identification and validation of an immune-related lncRNAs signature to predict the overall survival of ovarian cancer.用于预测卵巢癌总生存期的免疫相关长链非编码RNA特征的鉴定与验证
Front Oncol. 2022 Oct 12;12:999654. doi: 10.3389/fonc.2022.999654. eCollection 2022.

引用本文的文献

1
Novel risk model based on angiogenesis-related lncRNAs for prognosis prediction of hepatocellular carcinoma.基于血管生成相关长链非编码RNA的新型风险模型用于肝细胞癌预后预测
Cancer Cell Int. 2023 Aug 7;23(1):159. doi: 10.1186/s12935-023-02975-x.
2
Construction of Ovarian Cancer Prognostic Model Based on the Investigation of Ferroptosis-Related lncRNA.基于铁死亡相关 lncRNA 研究的卵巢癌预后模型的构建。
Biomolecules. 2023 Feb 6;13(2):306. doi: 10.3390/biom13020306.

本文引用的文献

1
Long non-coding RNA SNHG25 promotes epithelial ovarian cancer progression by up-regulating COMP.长链非编码RNA SNHG25通过上调COMP促进上皮性卵巢癌进展。
J Cancer. 2021 Jan 16;12(6):1660-1668. doi: 10.7150/jca.47344. eCollection 2021.
2
FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway.FAM83B通过抑制Wnt信号通路来抑制卵巢癌顺铂耐药。
Oncogenesis. 2021 Jan 9;10(1):6. doi: 10.1038/s41389-020-00301-y.
3
Integrated analysis of a competing endogenous RNA network reveals an 11-lncRNA prognostic signature in ovarian cancer.
竞争性内源性RNA网络的综合分析揭示了卵巢癌中的一种11长链非编码RNA预后特征。
Aging (Albany NY). 2020 Nov 20;12(24):25153-25171. doi: 10.18632/aging.104116.
4
lncRNA HEIH accelerates cell proliferation and inhibits cell senescence by targeting miR-3619-5p/CTTNBP2 axis in ovarian cancer.lncRNA HEIH 通过靶向 miR-3619-5p/CTTNBP2 轴促进卵巢癌细胞增殖并抑制细胞衰老。
Menopause. 2020 Nov;27(11):1302-1314. doi: 10.1097/GME.0000000000001655.
5
Predictive models for stage and risk classification in head and neck squamous cell carcinoma (HNSCC).头颈部鳞状细胞癌（HNSCC）分期及风险分类的预测模型
PeerJ. 2020 Sep 22;8:e9656. doi: 10.7717/peerj.9656. eCollection 2020.
6
m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells.m6A-YTHDF1介导的TRIM29上调促进顺铂耐药卵巢癌细胞的干细胞样表型。
Biochim Biophys Acta Mol Cell Res. 2021 Jan;1868(1):118878. doi: 10.1016/j.bbamcr.2020.118878. Epub 2020 Oct 1.
7
Identification of Potential Biomarkers and Related Transcription Factors in Peripheral Blood of Tuberculosis Patients.结核患者外周血中潜在生物标志物及相关转录因子的鉴定。
Int J Environ Res Public Health. 2020 Sep 24;17(19):6993. doi: 10.3390/ijerph17196993.
8
Bioinformatics analysis and verification of molecular targets in ovarian cancer stem-like cells.卵巢癌干细胞样细胞中分子靶点的生物信息学分析与验证
Heliyon. 2020 Sep 14;6(9):e04820. doi: 10.1016/j.heliyon.2020.e04820. eCollection 2020 Sep.
9
A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy.BRCA 突变型卵巢癌中两个长非编码 RNA 的新型标志物，可预测预后和化疗效果。
J Ovarian Res. 2020 Sep 19;13(1):112. doi: 10.1186/s13048-020-00712-w.
10
Overexpression of long noncoding RNA PTPRG-AS1 is associated with poor prognosis in epithelial ovarian cancer.长链非编码RNA PTPRG-AS1的过表达与上皮性卵巢癌的不良预后相关。
Rev Assoc Med Bras (1992). 2020 Jul;66(7):948-953. doi: 10.1590/1806-9282.66.7.948. Epub 2020 Aug 24.